coding variants in 14 genes especially RET and EDNRB have been identified which account for some HSCR cases. 5, 6 As a neurocristopathy, abnormal causes that have effects on proliferation, migration or differentiation during the initiation of embryonic period can lead to HSCR. 1 Previous studies manifested that some ncRNAs may be involved into the initiation and progression of HSCR, such as Circular RNA ZNF-609, lncRNA AFAP-AS, LOC100507600, miR-218 and HN12. [7] [8] [9] [10] [11] However, the molecular mechanism underlying the pathogenesis of HSCR still remains to be explored.
Long non-coding RNAs (lncRNAs) are a class of ncRNA exceeding 200 nucleotides in length, with no protein-coding or limited capacity. 12, 13 Accumulating reports indicate that lncRNAs function as an important role in various biological processes, such as embryonic development, gene imprinting, differentiation, proliferation and tumourigenesis. 14 LncRNAs also have the capacity to modulate gene expression at varieties of levels, including transcription, posttranscriptional modifications and translation. 15, 16 To date, mounting studies report that lncRNAs could act as competing endogenous RNAs (ceRNAs) to regulate the activities and biological functions of mRNAs by competitively binding to common miRNAs. 17 FAL1
(Refseq: NR_051960.1), a lncRNA located in 1q21.2 region of human genome, has been implicated in many diseases, such as prostate cancer, non-small cell lung cancer, melanoma and ovarian cancer. [18] [19] [20] [21] [22] [23] Although FAL1 plays pivotal roles in several diseases, little information available is regarding its functional processes in HSCR.
In this study, we uncovered that FAL1 was down-regulated in aganglionic tissues of HSCR and it may serve as a potential biomarker of HSCR. In addition, with overexpression or downregulation of FAL1 in 293T and SH-SY5Y cells, functional analyses were conducted to detect the contributions of FAL1 to occurrence and development of HSCR. Furthermore, we performed experiments to reveal the underlying mechanism of FAL1 acting as a ceRNA to regulate AKT1 at the post-transcriptional level in HSCR.
Overall, our results suggested that FAL1 might have relatively crucial performance for HSCR pathogenesis.
| MATERIAL S AND ME THODS

| Clinical patient samples and ethics statement
In this study, 64 pairs of HSCR aganglionic tissues and matched normal tissues were obtained from patients who underwent surgery in the Children's Hospital of Nanjing Medical University be- Table 1 .
| Cell lines and culture
We purchased the 293T and SH-SY5Y cell lines from the American Type Culture Collection (ATCC, Manassas VA, USA). The cells were maintained in Dulbecco's Modified Eagle medium (DMEM) medium (Hyclone, UT, USA) containing 10% foetal bovine serum FBS (Beyotime, Nantong, China), 100 μg/mL streptomycin and 100 IU/ mL penicillin (Invitrogen, Carlsbad, CA, USA). The culture condition was at 37°C in a humidified air with 5% carbon dioxide.
| Cell transfection
The FAL1 overexpressing plasmids, siRNAs against FAL1, miR-637 mimics and miR-637 inhibitors were all synthesized from GenePharma (Shanghai, China). All siRNAs and plasmids were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer's protocol. Detailed sequences were depicted in Table 2 . 
| RNA extraction and quantitative real-time PCR (qRT-PCR) detection
| Cell migration assay
The ability of cell migration was measured by utilizing transwell mi- 
| Cell cycle and apoptosis assay
For cell cycle analysis, the transfected cells were fixed by the 70% 
| Western blot assay
Proteins were isolated from fresh frozen tissues or treated cells by Radio Immunoprecipitation Assay (RIPA Beyotime, Nantong, China)
TA B L E 2 Sequences of primers for qRT-PCR and siRNA-related sequence
Name Sequence
miR-637 mimics Sense
5′-ACUGGGGGCUUUCGGGCUCUGCGU-3′
Antisense
5′-GCAGAGCCCGAAAGCCCCCAGUUU-3′
miR-637 inhibitor
buffer. The total proteins were electrophoresed on 10% sodium do- 
| RE SULTS
| Expression levels of FAL1 in HSCR patients' samples
With the view of elucidating whether FAL1 was dysregulated in HSCR, we detected FAL1 expression levels in HSCR tissues (n = 64) and normal control tissues (n = 64) by using qRT-PCR. The age, body weight and gender of patients were obtained when collecting samples and no statistically significant difference was observed between HSCR patients and matched control group. As evident from Figure 1A , FAL1 levels were significantly decreased in HSCR tissues compared with the normal samples. Since the underlying diagnostic value of lncRNAs has been reported in some diseases, 24, 25 Receiveroperating characteristic (ROC)-curve analysis was then conducted to verify whether FAL1 can distinguish HSCR patients from normal controls. The area under the curve (AUC) was 0.81, suggesting that FAL1 may be a potential biomarker for HSCR patients. (Figure 1B ).
| Effect of FAL1 in cell lines
To investigate the biological functions of FAL1 in HSCR, the expression of FAL1 was silenced in 293T and SH-SY5Y cells through transfecting siRNAs targeting FAL1. What is more, we also overexpressed FAL1
by transfecting plasmids for further confirmation. We found that siRNAs could efficaciously inhibit the FAL1 expression ( Figure S1A Figure 2D ). However, knockdown of FAL1 had no effect on cell apoptosis ( Figure S1C ).
| Subcellular localization of FAL1
It is generally known that the subcellular localization of lncRNAs determines how to exert its biological functions. To confirm the cellular localization of FAL1, cells were separated into cytoplasm and nucleus. GAPDH and U6 were used as control. GAPDH was mainly found in the cytoplasm fractions, while U6 distributed mostly in the nucleus. The results of qRT-PCR showed that FAL1 was detected 74.7% and 72.1% in the cytoplasm fractions in 293T and SH-SY5Y cells respectively ( Figure 3A) . The results indicated that FAL1 may play a part in HSCR probably at the post-transcriptional level.
The expression of FAL1 in HSCR. A, The expression of FAL1 was analysed in HSCR aganglionic tissues (n = 64) and relatively normal tissues (n = 64) by qRT-PCR. FAL1 was significantly reduced in patients' aganglionic tissues compared with control tissues. B, Receiver-Operating Characteristic (ROC) curve analysis of the diagnostic potential of FAL1 in HSCR tissues. ***P < .0001, data represent the mean ± SD
| FAL1 is targeted by miR-637
Although we found that FAL1 was significantly suppressed in HSCR tissues and could inhibit cell proliferation and migration, how it resulted in the occurrence of HSCR was unclear. Given that 
| FAL1 regulates the miR-637 target gene, AKT1
To investigate the molecular mechanism by which miR-637 exerts its biological effects, miR-637 target genes were screened by bioinformatic prediction (TargetScan, miRWalk, PicTar, RegRNA). Based on the sequence complementarity to miR-637 seed sequence and functional analysis, we selected AKT1 (AKT serine/threonine kinase 1) for further study, which has been identified as the target of miR-637 in gliomas. 26 To verify whether miR-637 directly targeted AKT1 in HSCR, the luciferase reporter assay was conducted. The luciferase reporter plasmids pGL3-AKT3-Wild and pGL3-AKT3-Mut which included predicted or mutant binding sites were constructed and co-transfected with miR-637 mimics or negative control in 293T
and SH-SY5Y cells respectively ( Figure 4A ). The results validated that the luciferase intensity of the WT reporter was repressed when miR-637 was overexpressed, while no changes of luciferase activity were observed in the MUT reporter after transfection of miR-637 mimics ( Figure 4B ). All the findings provide evidence that AKT1 was a biological binding target of miR-637. Then, the expression levels of AKT1 were measured in HSCR tissues by qRT-PCR. As depicted in Figure 4C , the mRNA levels of AKT1 were considerably decreased in HSCR tissues compared with negative controls. In addition, we detected the protein levels of AKT1 by western blotting analysis and the conclusion was consistent with qRT-PCR results ( Figure 4D ).
Furthermore, Bivariate correlation analysis was processed to assess the interactions between FAL1, miR-637 and AKT1 at mRNA level in the tissues (Figure 4E-G) . According to the analysis, we found that Collectively, all findings verified that FAL1 positively regulated the expression of AKT1 via directly binding to miR-637.
F I G U R E 4 AKT1 is the direct target of miR-637.A, The putative miRNA-binding sites in the AKT1 sequence. The putative miRNAs recognition sites were cloned downstream of the luciferase gene and named pGL3-AKT1-Wild. Bottom: mutations in the AKT1 sequence to create the mutant luciferase reporter constructs named pGL3-AKT1-Mut. B, 293T, SH-SY5Y cells were transfected with full-length 3′-UTR (wild type or mutant) of AKT1, and the luciferase reporter was performed to confirm the direct target sites. C, Relative expression of AKT1 in HSCR tissues in comparison with control tissues. AKT1 was significantly reduced in patients' tissues. D, Protein level of AKT1 in HSCR tissues and normal control samples was detected by Western Blot. E, Bivariate correlation analysis of the relationship between FAL1 and AKT1 expression level. F, There was a significantly negative correlation between the expression level of FAL1 and the expression level of miR-637 in the same paired intestinal samples (R = −.4527, P < .001, Pearson). G, There was a significantly negative correlation between the expression level of AKT1 and the expression level of miR-637 in the same paired intestinal samples (R = −.4360, P < .001, Pearson). **P < .01, ***P < .0001, data represent the mean ± SD
| FAL1-miR-637 regulatory loop plays a vital role in cellular functions
We next examined whether miR-637 affected cell proliferation and migration in 293T and SH-SY5Y cells. The expression levels of miRNA were elevated by miRNA mimics and attenuated by miRNA inhibitor . GAPDH served as a loading control. *P < .05, **P < .01, ***P < .0001, ns, no significant difference, data represent the mean ± SD F I G U R E 6 FAL1 regulates cell function through miR-637.(A and B) EdU assay and CCK8 assay were performed to determine the proliferation of miR-637-transfected cells and treated with miR-637 mimics plus FAL1 expression plasmid. C, The migration ability with respect to changes of 293T and SH-SY5Y cell lines after co-transfection of miR-637 mimics and FAL1 overexpression plasmids was qualified by transwell assay. D, EdU assay was performed to determine the proliferation of cells treated with FAL1-MUT overexpression plasmid. E, The migration ability with respect to changes of 293T and SH-SY5Y cell lines after transfection of FAL1-MUT overexpression plasmid was qualified by transwell assay. F, Cell cycle was detected by BD Biosciences FACS Calibur Flow Cytometry after cells treated with FAL1-MUT overexpression plasmid in 293T and SH-SY5Y cell lines. *P < .05, **P < .01, ***P < .0001, ns, no significant difference, data represent the mean ± SD
| D ISCUSS I ON
HSCR is a common malformation of the digestive tract caused by the failure of ENCCs to migrate to hindgut during embryogenesis from 5 to 12 weeks. 27 Recently, Langer et al proposed a different theory which suggests that ganglion cells are able to reach the distal intestine but fail to proliferate or survive. 28 Therefore, any causes affect the proliferation and migration of ENCCs may result in the occurrence of HSCR. LncRNAs have been proved as regulators of almost every cellular process, and dysregulation of these non-coding molecules seems to be associated with the development of different diseases. Since FAL1 was identified to be involved in cell proliferation and migration, we hypothesized that FAL1 could play a part in the pathogenesis of HSCR.
In our previous study, we reported that the expression of Receptor expression by binding to miR-124 in Bladder Cancer. 29 Li et al identified that lncRNA-PETNP1 modulates PETN expression by sponging miR-19b in breast cancer. 30 Hu et al reported that lncRNA-PART-1 controls the expression of DNMT3A through combining with miR-143 in colorectal cancer. 31 We focused on miR-637 which has higher scores sponging FAL1 by integrating online bioinformatics database. Then, luciferase reporter assay and RIP assay were carried out to further validate the association between FAL1 and miR-637. These observations implied that miR-637 could decrease the intensity of luciferase activity of pGL3-lncRNA-FAL1-Wild and FAL1 and miR-637 could be pulled down by anti-Ago2, which indicated that FAL1 could directly bind to miR-637. Over recent years, miR-637 has been verified to suppress the growth of tumour in multiple diseases, such as glioma, hepatocellular carcinoma and ovarian cancer. 26 ,32,33 Furthermore, we also identified that the transfection of miR-637 mimics suppressed the cell proliferation and migration, which had similar impacts as down-regulation of FAL1. Taken together, these findings proved that FAL1 affected cellular progression by interacting with miR-637.
To explore the mechanism underlying the repression of cell proliferation and migration mediated by miR-637, we identified AKT1 as the target of miR-637 by luciferase assay. AKT1 is one of 3 AKT kinase, which modulates a number of cell processes containing cell proliferation, apoptosis, differentiation and tumour formation. Elevated expression of AKT1 could make contributions to glioma progression 34 and was involved in multiple cellular signal pathways affecting cell survival, migration and invasion in glioma cells. 26 Targeting AKT1 might be an efficient way to repress the development of hepatocellular carcinoma. 35 Our findings also show that FAL1 may be a potential biomarker for HSCR diagnosis.
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